Semaglutide 1.5mg Tablets: What the Starting Dose Actually Does

Why the evidence base for Wegovy tablets starts at 1.5mg

The OASIS 4 trial, which underpinned the MHRA's June 2026 approval, enrolled 307 adults with obesity or overweight and at least one weight-related condition. Participants had no diabetes. Over 64 weeks, the oral semaglutide group began at 1.5mg and titrated upward under clinical guidance; among those who stayed fully adherent to the schedule, average weight loss reached approximately 17%, framed correctly, that figure applies to the adherent subgroup, not the overall population. The overall average of around 13.6% is the headline the MHRA and Novo Nordisk cite.

What this tells us about the 1.5mg dose specifically: it is not where the weight-loss effect concentrates. The approved schedule (1.5mg, then 4mg, then 9mg, then 25mg maintenance, with at least a month at each level) is designed so that early exposure to a low amount of semaglutide dampens the gastrointestinal response before higher doses are introduced. In the trial, around three quarters of oral semaglutide participants reported GI effects, most commonly nausea; these were generally mild-to-moderate and transient, consistent with what is seen across the GLP-1 class. Starting low is how the medicine earns longer-term tolerability. The NHS medicines page for semaglutide covers the side-effect profile in detail.

For readers curious about how dose and weight loss relate across the full schedule, the semaglutide tablet dose and weight loss page covers that relationship with the trial evidence behind each level.

What happens at 1.5mg day-to-day: taking it correctly matters more here than at any other stage

Oral semaglutide absorption depends on a strict fasting protocol. The tablet contains semaglutide co-formulated with an absorption enhancer (SNAC), but that mechanism only works reliably in an empty, low-acid stomach. The instructions in the approved Patient Information Leaflet are clear: first thing in the morning, swallow the tablet whole with no more than around 120ml of plain water, then wait a minimum of 30 minutes before consuming anything else, food, coffee, juice, other tablets. This is not optional fine print; it is the window the medicine needs to cross the stomach lining.

For people whose mornings involve school runs or early commutes, building this into a routine before the kettle goes on tends to be the simplest anchor point. The tablet goes in, the timer runs, breakfast follows. Missing the window by eating first effectively reduces absorption and may blunt the dose's effect even at later, higher levels. Your prescriber or the PIL will confirm the exact protocol for your circumstances.

Storage is less involved than with the injection: room temperature, away from direct heat and moisture. No freezer risks, no fridge-door logistics. Travel is correspondingly simpler, though as always your prescriber should know if anything changes in your routine or health. Details on how the full oral dose schedule is structured are at the semaglutide tablets dosing page.

Who the Wegovy tablet starting dose is licensed for, and what a prescriber weighs up

The MHRA licence for Wegovy tablets covers adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related condition such as high blood pressure, dyslipidaemia, or obstructive sleep apnoea. The medicine is to be used alongside a reduced-calorie diet and increased physical activity. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance, a prescriber will apply the correct threshold for each individual.

BMI alone does not determine suitability. Before anyone begins at 1.5mg, a clinician reviews the full picture: current medicines, medical history, contraindications. Oral semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive, and it is not licensed for under-18s. Anyone with a history of medullary thyroid carcinoma, certain GI conditions, or pancreatitis will need a detailed prescriber conversation before treatment is considered.

It is also worth being clear about what the 1.5mg tablet is not. The 3mg, 7mg and 14mg tablet strengths belong to Rybelsus, a different semaglutide product licensed for type 2 diabetes, not for weight loss; if you want to understand how the semaglutide 7mg tablet relates to weight loss, that page explains why it sits outside the Wegovy schedule. The Wegovy weight-loss tablet schedule runs 1.5mg, 4mg, 9mg, and 25mg only. If you have seen references to those other strengths in a weight-loss context, the semaglutide 3mg tablet page explains the distinction, and our page on the semaglutide 14mg tablet covers where that strength fits within the Rybelsus diabetes indication. For context on where the oral route sits relative to other treatment options, the weight-loss treatment overview sets out the broader picture, and treatment pricing is covered separately.

Getting a prescription for oral semaglutide through a regulated UK pharmacy

As a prescription-only medicine, Wegovy tablets (including the 1.5mg starting dose) require a clinical consultation before they can be dispensed. The only legal route is a prescriber assessing your suitability and issuing a prescription; dispensing then happens through a pharmacy registered with the General Pharmaceutical Council, which you can verify at the GPhC pharmacy register. Any seller offering these tablets without a prescription, or at prices that seem implausibly low, warrants caution, the MHRA has been clear about the risks of medicines obtained outside the licensed supply chain.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber, not processed by an algorithm. There is no subscription and no auto-renewal; each repeat order goes through fresh clinical review. If you are ready to find out whether oral semaglutide is suitable for you, check your eligibility with a free consultation, our clinical team reviews same-day for orders placed before 12pm Monday to Friday.